rPFS and cPFS May Act as Surrogate OS End Points in Phase 3 mHSPC Clinical Trials

Radiographic and clinical progression-free survival may be surrogates for overall survival in hormone-sensitive prostate cancer clinical trials.

Related Keywords

North Carolina ,United States ,Jamesb Duke ,Susan Halabi ,Duke Cancer Institute In Durham ,Division Of Biostatistics ,Distinguished Professor ,Duke Cancer Institute ,Surrogacy Analysis ,Journal Of Clinical Oncology ,Phd ,Progression Free Survival ,Overall Survival ,Hormone Sensitive Prostate Cancer ,Clinical Trials ,Surrogates ,Rpfs And Cpfs Are Surrogates For Os ,Rpfs ,Cpfs ,Phase 3 Clinical Trials ,Testosterone Suppression Based Treatment Strategies ,